Last updated on August 2018

Entyvio (Vedolizumab) Long Term Safety Study


Brief description of study

The purpose of this study is to assess the long-term safety of vedolizumab versus other biologic agents in participants with Ulcerative Colitis (UC) or Crohn's Disease (CD).

Detailed Study Description

The drug being tested in this prospective, observational study is called vedolizumab. Vedolizumab is being used to treat people who have UC or CD. This study will look at the long-term safety of vedolizumab versus other biologic agents in participants with UC or CD. The study will enroll approximately 5000 participants. All participants enrolled in this will belong to one of the two treatment group:

  • Vedolizumab
  • Other Biologic Agents -adalimumab, certolizumab pegol.

Golimumab and infliximab. Study drugs will be prescribed by the physician according to local prescribing information in the participating countries. This multi-centre trial will be conducted worldwide. The overall time to participate in this study is 7 years. Participants will make visits at every 6 months to their treating physician.

Clinical Study Identifier: NCT02674308

Contact Investigators or Research Sites near you

Start Over

Takeda Study Registration Call Center

Louisiana Research Center, Llc
Shreveport, LA United States
9.52miles
  Connect »